SCHEMBL259085

SCHEMBL259085

NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.64
ECE1 P42892 1/20 0.39
FOLH1 Q04609 1/20 0.39
GHSR Q92847 1/20 0.38
SLC6A5 Q9Y345 1/20 0.37
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37
GNPAT O15228 1/20 0.36
ERAP2 Q6P179 1/20 0.36
LNPEP Q9UIQ6 1/20 0.36
CALCRL Q16602 2/20 0.36
NAALAD2 Q9Y3Q0 1/20 0.35
DHFR P00374 1/20 0.35
FPGS Q05932 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8832939 1.00 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL10595108 1.00 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL5598418 1.00 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL259084 1.00 SLC15A2 (0.64) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL2815080 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL29767981 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL4589314 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL29473319 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL4589903 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5
SCHEMBL2817828 0.99 SLC15A2 (0.63) SLC15A2ECE1FOLH1GHSRSLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1012 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747264-A1 MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE University of Reading (GB) 2026-05-27 EP claimed
US-20260115258-A1 PEPTIDE COMPOSITIONS FOR TREATING HAIR LOSS RESTORE BIOLOGICS HOLDINGS LLC (US) 2026-04-30 US claimed
WO-2026040002-A1 COMPOSITION AND METHOD FOR CARING FOR THE SKIN L'OREAL (FR) 2026-02-26 WO claimed
US-20250295762-A1 COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-09-25 US claimed
WO-2025109216-A1 COSMETIC COMPOSITION COMPRISING A MIXTURE OF PEPTIDES LABAREAU B.V. (NL) 2025-05-30 WO claimed
CN-115944710-B Blue copper peptide composition and application thereof 上海湃肽生物科技有限公司 2025-05-27 CN claimed
CN-119661633-A Method for full liquid phase synthesis of blue copper peptide 湖南益安生物科技有限公司 2025-03-21 CN claimed
CN-119638822-A Full liquid phase synthesis method of oligopeptide-1 湖南益安生物科技有限公司 2025-03-18 CN claimed
CN-119060121-B Synthesis method of oligopeptide-1 山东美欣生物科技有限公司 2025-03-14 CN claimed
US-20250073157-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HAIR LOSS VIAS PARTNERS, LLC 2025-03-06 US claimed
US-4937230-A ADMINISTERING GLYCYL-HISTIDYL-LYSINE COPPER DERIVATIVE PROCYTE CORPORATION (US) 1990-06-26 US claimed
WO-1989012441-A1 COSMETIC AND SKIN TREATMENT COMPOSITIONS PROCYTE CORPORATION (US) 1989-12-28 WO claimed
EP-0316408-A1 METHOD OF TUMOR INHIBITION IN WARM-BLOODED ANIMALS PROCYTE CORPORATION (US) 1989-05-24 EP claimed
EP-0313643-A1 METHODS AND COMPOSITIONS FOR PREVENTING ULCERS. PROCYTE CORP (US) 1989-05-03 EP claimed
WO-1988008714-A1 METHODS AND COMPOSITIONS FOR PREVENTING ULCERS PROCYTE CORPORATION (US) 1988-11-17 WO claimed
WO-1988008715-A1 METHOD OF TUMOR INHIBITION IN WARM-BLOODED ANIMALS PROCYTE CORPORATION (US) 1988-11-17 WO claimed
US-4767753-A GLYCYL-HISTIDYL-LYSINE DERIVATIVES PROCYTE CORPORATION (US) 1988-08-30 US claimed
US-4760051-A Administering to animal a therapeutical amount of glycine -histidine-lysine copper(ii) PROCYTE CORPORATION, A CORP. OF WA. 1988-07-26 US claimed
US-4732155-A Implantable chemoattractant system THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1988-03-22 US claimed
EP-0189182-A2 Use of a compound containing GHL-Cu for the manufacture of a medicament for healing wounds PROCYTE CORPORATION (US) 1986-07-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295762-A1 COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF BMP2, BMP1, MATR3 SLC15A2 3505/4885ECE1 3077/4885FOLH1 3277/4885
US-20260115258-A1 PEPTIDE COMPOSITIONS FOR TREATING HAIR LOSS PTMS, CHI3L1, CHI3L2 SLC15A2 3871/4885ECE1 4542/4885FOLH1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.